Liquidia Corp

LQDA Biotech & pharma

Develops inhalation powders for pulmonary arterial hypertension.

Jun 2026Revenue $451M/yrExpenses $282M/yr
Reached break-even Feb 2026
Figures by year

When did Liquidia become profitable?

Its revenue passed its expenses in Feb 2026. In the 12 months to Jun 2026, revenue was $451M and expenses $282M.

Fiscal year toRevenueExpensesOperating profit
Dec 2025$158M$210M−$51.4M
Dec 2024$14.0M$135M−$121M
Dec 2023$17.5M$90.9M−$73.4M
Dec 2022$15.9M$54.7M−$38.8M
Dec 2021$12.9M$46.6M−$33.8M
Dec 2020$740K$59.8M−$59.1M
Dec 2019$8.07M$54.9M−$46.8M